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Abstract
Background: Hantavirus infections cause potentially life-threatening disease in humans world-wide. Infections with
American hantaviruses may lead to hantavirus pulmonary syndrome characterised by severe cardiopulmonary
distress with high mortality. Pulmonary involvement in European Puumala hantavirus (PUUV) infection has been
reported, whereas knowledge of potential cardiac manifestations is limited. We aimed to comprehensively
investigate cardiopulmonary involvement in patients with PUUV-infection.
Methods: Twenty-seven hospitalised patients with PUUV-infection were examined with lung function tests, chest
high-resolution CT (HRCT), echocardiography including speckle tracking strain rate analysis, ECG and measurements of
cardiac biomarkers N-terminal pro-B-type natriuretic peptide (NT-ProBNP) and troponin T. Patients were re-evaluated
after 3 months. Twenty-five age and sex-matched volunteers acted as controls for echocardiography data.
Results: Two-thirds of the patients experienced respiratory symptoms as dry cough or dyspnoea. Gas diffusing capacity
was impaired in most patients, significantly improving at follow-up but still subnormal in 38%. HRCT showed thoracic
effusions or pulmonary oedema in 46% of the patients. Compared to controls, the main echocardiographic findings in
patients during the acute phase were significantly higher pulmonary vascular resistance, higher systolic pulmonary
artery pressure, lower left ventricular ejection fraction and impaired left atrial myocardial motion. Pathological ECG,
atrial fibrillation or T-wave changes, was demonstrated in 26% of patients. NT-ProBNP concentrations were markedly
increased and were inversely associated with gas diffusing capacity but positively correlated to pulmonary vascular
resistance. Furthermore, patients experiencing impaired general condition at follow-up had significantly lower gas
diffusing capacity and higher pulmonary vascular resistance, compared to those feeling fully recovered.
Conclusions: In a majority of patients with PUUV-infection, both cardiac and pulmonary involvement was
demonstrated with implications on patients’ recovery. The results demonstrate vascular leakage in the lungs that most
likely is responsible for impaired gas diffusing capacity and increased pulmonary vascular resistance with secondary
pulmonary hypertension and right heart distress. Interestingly, NT-ProBNP was markedly elevated even in the absence
of overt ventricular heart failure. The method of simultaneous investigations of important cardiac and respiratory
measurements improves the interpretation of the underlying pathophysiologic mechanisms.
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Background
Hantaviruses are rodent-borne RNA viruses that cause
potentially lethal infections in humans worldwide [1].
The disease is generally transmitted by inhalation of viral
particles shed in rodent excreta [2,3]. Typical clinical
features of hantavirus infection include a capillary-leak
syndrome with hypotension and oedema, together with
coagulopathy and general symptoms such as high fever,
headache and myalgia [1]. In Eurasia, hantavirus strains
cause haemorrhagic fever with renal syndrome (HFRS),
while hantaviruses in North and South America cause
hantavirus pulmonary syndrome (HPS; also denominated
hantavirus cardiopulmonary syndrome), leading to severe
and often fatal heart and lung failure [1,4-6].
Infection with the European Puumala hantavirus (PUUV)
causes a mild HFRS, characterised by coagulopathy and
acute renal failure [7]. In addition, pulmonary involve-
ment is very common in PUUV-infection, ranging from
mild symptoms to severe lethal forms similar to HPS
[8-12]. Previous studies of patients with HPS and PUUV-
related HFRS have shown impaired lung function, pleural
effusion and pulmonary oedema [4-6,9,13,14], along with
an activated lower airway immune response reported in
both syndromes [11,12,15-17]. Only few studies have
addressed heart function in patients with hantavirus
infection [5,9,18,19]. Electrocardiographic (ECG) abnor-
malities, including sinus bradycardia and T-wave changes,
have been described in 35-57% of European patients with
HFRS [18,19]. Echocardiographic data from PUUV-
infected patients have mainly included information of
morphological and visual descriptions of left ventricle
function [9,19], however with few details of right heart
function that more likely would be influenced as a
consequence of PUUV-related manifestations within
the lungs.
In the present study, we aimed to comprehensively
study cardiopulmonary involvement in patients with PUUV-
related HFRS using detailed state-of-the-art echocardi-
ography including speckle tracking technique, ECG and
cardiac biomarkers, together with high-resolution CT
(HRCT) of the chest and lung function tests. We hypothe-
sised that PUUV would target the lungs causing signs of
pulmonary capillary leakage and impaired gas diffusing
capacity, along with related changes in heart function.
Methods
Subjects
Twenty-seven hospitalised patients (18 women; median
age 54 years, range 19–82 years) with serology-verified
PUUV-infection admitted to the Department of Infec-
tious Disease at the University Hospital, Umeå, Sweden,
were included in a prospective study between January 2008
and March 2011. Within the same time-span another 20
patients (8 women) with PUUV-infection were hospitalised
at our clinic, but were not included due to short hospi-
talisation (<2 days, n = 7), declined study participation
(n = 8) or logistical reasons (i.e. public holidays, n = 5).
Twenty-one patients were previously healthy. Out of the
remaining six patients, one patient had well-regulated
hypertensive heart failure, chronic obstructive pulmonary
disease and a history of transient atrial fibrillation; one
patient was treated for hypertension, had type-II diabetes
and previous transient atrial fibrillation; one patient had
type-II diabetes, rheumatic arthritis, Parkinson’s disease
and was treated for hypertension; two patients were
treated for hypertension and one patient received treat-
ment for allergic asthma. Nineteen patients were non-
smokers and eight were smokers, defined as current
smoking or having smoked within the last 2 years.
Cardiopulmonary involvement was studied in the acute
phase during hospitalisation and patients were re-evaluated
at follow-up after 3 months. Clinical data was retrieved
from the patients’ medical charts. One patient declined
follow-up investigation. Twenty-five healthy age and sex-
matched volunteers acted as control group for echocardio-
graphic data. Echocardiographic data from a patient with a
history of heart failure and pulmonary disease was omitted
from comparison with controls. Furthermore, this patient
did not undergo lung function tests or HRCT. The
study was approved by the Regional Ethics Review
Board at Umeå University. Participants were treated
according to the Declaration of Helsinki and all gave
written informed consent.
Lung function
Lung function was evaluated using computerised Jaeger
equipment (Würzburg, Germany) according to guidelines
[20,21]. Vital capacity (VC), total lung capacity (TLC),
forced expiratory volume in 1 second (FEV1), FEV1/VC
and diffusing capacity of the lung for carbon monoxide
(DLCO) using the single-breath method were recorded.
Results were expressed as percentage of predicted value
for each patient using European reference values [22,23].
High-resolution computed tomography
HRCT studies of the lungs were performed with a 64-slice
scanner (LightSpeed VCT, GE Healthcare, Milwaukee,
WI, USA), without administration of intra-venous con-
trast. Images were obtained in one spiral series during
full inspiration in supine position from lung apex to
costo-phrenic angle and were then reconstructed into
slice thickness 1.25 mm with 10 mm interval. Imaging
parameters were 120 kV, mA min-max 150–700 and
noise index 35. Reconstruction kernel for the thin slices
was “bone plus” and window settings for viewing lung
parenchyma were W1600/L-400 and for soft tissue
W350/L50.
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Echocardiography
Echocardiographic examinations, measurements and ana-
lyses were performed by one examiner (P.L.), using a Vivid
7 echocardiograph (GE Medical Systems, Horten, Norway)
equipped with an adult 1.5-4.3 MHz phased array trans-
ducer. Standard views from the parasternal long and
short axis as well as apical four-chamber views were ob-
tained. Blood flow velocities were acquired as proposed
by American Society of Echocardiography [24]. All re-
cordings were performed with a superimposed ECG.
Off-line analysis was made using a commercially avail-
able software system (EchoPac version 8.0.1, GE Health-
care, Waukesha, WI, USA). Measurements of left atrial
(LA) and ventricular (LV) dimensions including septal
and posterior wall thickness were determined as recom-
mended [25,26]. From the apical four-chamber view LV
volumes at end-systole and end-diastole were measured
and LV ejection fraction was estimated using Simpson’s
bi-plane model [26]. Doppler recordings of LV filling
measurements were made of trans-mitral early (E) and
late diastolic (A) velocities calculating E/A ratio, together
with E-wave deceleration time and isovolemic relaxation
time (LV IVRT, expressed as ratio of the previous R-R
interval from ECG), all used as a means to evaluate LV
diastolic function [27]. From pulmonary venous flow, the
systolic (S) and diastolic (D) flow velocities were measured
and the S/D ratio was calculated, as additional aid to
assess LV diastolic function [27]. Stroke volume was
measured using stroke distance from LV outflow-tract
systolic flow and cross-sectional area [24]. Cardiac out-
put was calculated from stroke volume x heart rate. The
peak gradient between right ventricle (RV) and right
atrium was measured, using the simplified Bernoulli for-
mula [24]. From that gradient, an estimated right atrial
pressure of 7 mm Hg was added for all to calculate peak
systolic pulmonary artery pressure (sPAP). Mean PAP
was calculated from sPAP × 0.62 + 2 [28]. Pulmonary
vascular resistance (PVR) was calculated from the equa-
tion mean PAP - estimated pulmonary capillary wedge
pressure of 10 mmHg / cardiac output, as previously de-
scribed [29]. From the same view, tricuspid annular
plane systolic excursion (TAPSE) was determined, as an
indirect measure of RV ejection fraction [30]. Pulmonary
artery acceleration time was determined as a means to
detect increased PVR [31]. From the RV free wall, RV
IVRT was measured and indexed to the previous R-R
interval [32]. Myocardial function measured both in LA
and LV was assessed using speckle tracking echocardi-
ography technique, from the apical four-chamber view
as previously described [33,34]. Using this technique,
measurements of mean strain rate in six segments of
the LA and LV were performed. LA and LV strain rate
values during ventricular systole, early diastole and late
atrial diastole were then determined.
Electrocardiography
Resting 12-lead ECG was recorded in the acute phase
and at follow-up and was analysed by one examiner (M.H.).
Measurements of cardiac biomarkers and routine
laboratory analyses
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
and high-sensitivity cardiac troponin T (hs-cTnT) were
analysed in plasma according to clinical routine at an
accredited laboratory at the Department of Clinical
Chemistry at Umeå University hospital. Samples were
taken on day of inclusion, then every second day during
hospitalisation and at follow-up. Similarly, C-reactive
protein (CRP), lactate dehydrogenase, albumin, creatinine,
D-dimer, fibrinogen and PK-INR were analysed, along
with blood leukocyte and platelet counts.
DIC-scoring
Patients were scored for presence of disseminated intra-
vascular coagulation (DIC) according to templates based
on the International Society on Thrombosis and Haemo-
stasis criteria as described previously [35]. Overt DIC
was indicated by a score of ≥5 points.
Statistical analysis
SPSS (version 20.0; IBM, Armonk, NY, USA) was used
for statistical analysis. As most variables included small
sample numbers and thus not expected to be normally
distributed, non-parametric tests were used. Continuous
variables were expressed as median (25th-75th percen-
tiles) unless stated otherwise. Mann–Whitney U test was
used for group comparisons and Wilcoxon signed-ranks
test was used for paired within-group observations. Fisher’s
exact test was used for comparisons of categorical data.
Spearman’s correlation coefficient was used to test for
correlations. All tests were two-sided and P-values < 0.05
were considered statistically significant.
Results
Clinical data
All 27 patients experienced symptoms typical for PUUV-
infection and were hospitalised for 5 (4–7) days. Clinical
findings and laboratory results are presented in Table 1.
One-third of the patients were hypotensive (systolic
blood pressure ≤ 90 mg Hg). Respiratory tract symptoms
were present in 67%, most frequently expressed as mild
to moderate dyspnoea or dry cough. Lowest pulse oximetry
saturation when breathing ambient air was 94% (92–96)
and 33% were given supplemental oxygen treatment.
Patients requiring oxygen treatment had significantly
higher creatinine levels and leukocyte counts, together
with lower nadir albumin, when compared to those
without need for oxygen (Table 2). Thrombocytopenia
(platelet count <145 109 L-1) and transient renal failure
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(indicated by creatinine >150 μmol L-1) were seen in 93%
and 63% of the patients respectively. Compared to weight
on admission, patients’ weight gain was 0.9 kg (0–2.4)
during hospitalisation. No patient experienced chest pain,
no one received dialysis and all survived. One patient
required intensive-care treatment for pulmonary oedema
and hypotension, receiving non-invasive mechanical venti-
lation and intra-venous fluid therapy. In another patient,
the clinical course was complicated by pulmonary embo-
lism diagnosed 19 days post onset of PUUV-infection and
one patient developed a profusely bleeding duodenal ulcer
12 days after onset of disease.
At follow-up (n = 26), patients were generally recove-
ring. However, 13 patients (50%) reported impaired general
condition, described as tiredness or fatigue, out of which
six patients (23%) were still experiencing effort dyspnoea.
Lung function
In the acute phase, 20 patients (80%) showed subnormal
results (<80% of predicted value) for DLCO, while other
parameters were within normal limits (Table 3). Patients
requiring oxygen treatment had significantly lower DLCO,
compared to patients not in need of oxygen (Table 2).
There was no statistical difference in lung function when
comparing female and male patients (data not shown).
Although DLCO had significantly improved at follow-
up (Table 3), nine patients (38%) were still displaying
subnormal DLCO. Furthermore, patients experiencing
impaired general condition at follow-up had significantly
lower DLCO, compared to those feeling fully recovered
(Table 2).
High-resolution computed tomography
Abnormal chest HRCT was evident in 14 patients (58%).
Thoracic effusions or pulmonary oedema (Figure 1) were
found in 11 patients (46%). Enlarged thoracic lymph nodes
and pneumonic infiltrates were also detected (Table 3).
Patients with abnormal chest HRCT had lower DLCO
(P < 0.05), higher CRP (P < 0.05), higher leukocyte count
(P = 0.053) and were more likely to require oxygen treat-
ment (P < 0.05), compared to patients with normal chest
HRCT (data not shown). Patients with pulmonary oedema
had higher leukocyte count (P < 0.05) and lactate dehydro-
genase concentration (P < 0.05), lower nadir platelet count
(P < 0.05) and a non-significantly lower DLCO (P = 0.064),
compared to patients without pulmonary oedema (data
not shown). There was no statistical difference in ma-
ximum creatinine concentrations between patients with
abnormal HRCT or pulmonary oedema and those with
normal findings (P = 0.241 and P = 0.197 respectively,
data not shown).
Pathological HRCT findings were re-evaluated and nor-
malised in all but one patient who 93 days after PUUV-
infection had a progression of pulmonary oedema that
was fully resolved when re-investigated after 240 days
(Table 3).
Echocardiography
Echocardiography findings showed that patients had sig-
nificantly higher heart rate, lower LV ejection fraction,
longer LV IVRT, larger systolic LV diameter and thinner
LV posterior wall, when compared to controls (Table 4).
Investigations of right heart function revealed that pa-
tients had significantly higher PVR and sPAP whereas
pulmonary artery acceleration time was shorter, compared
with controls. There was also a tendency to a longer RV
IVRT in patients (P = 0.057, Table 4). Compared to con-
trols, results from speckle tracking echocardiography re-
vealed impaired atrial myocardial function in patients,
indicated by significantly reduced strain rate during the
late diastolic atrial contraction phase, measured both in
Table 1 Clinical findings and laboratory results in acute
phase and at follow-up in Puumala hantavirus infection
Acute phase Follow-upa
Number of patients 27 26
Clinical findings
Hypotension (≤90 mmHg) 9 (33%) 0
Respiratory symptoms 18 (67%) 6 (23%)
Dyspnoea 14 (52%) 6 (23%)
Dry cough 10 (37%) 0
Oxygen treated 9 (33%) 0
Acute renal failureb 17 (63%) 0
Oliguria (<400 mL/24 hours) 3 (11%) 0
Laboratory results
Leukocyte count max (3.5-8.8 109/L) 8.8 (7.0-12.3) 6.4 (5.3-8.1)
CRP max (<3 mg/L) 115 (47–166) <3 (<3- < 3)
Platelet count min (145–387 109/L) 66 (51–90) 249 (208–304)
D-dimer max (<0.2 mg/L) 1.1 (0.7-1.7) 0.1 (0.1-0.2)
Creatinine max (<105 μmol/L) 177 (121–304) 69 (57–92)
Lactate dehydrogenase max
(<3.4 μkat/L)
4.9 (4.3-6.4) 3.1 (2.8-3.5)
Albumin min (36–45 g/L) 28 (22–30) 45 (42–47)
Cardiac biomarkers
NT-proBNP inclusion (<150 ng/L) 646 (222–1568) -
NT-proBNP max (<150 ng/L) 1768 (585–5067) 62 (32–130)
hs-cTnT max (<15 ng/L) 7 (0–16) 0 (0–7)
aLaboratory parameters normalised at follow-up (P < 0.001 for all, Wilcoxon
signed-ranks test), compared to the acute phase, b Defined as creatinine
concentration >150 μmol L-1. CRP, C-reactive protein; hs-cTnT, high-sensitivity
cardiac troponin T; max, maximum; min, minimum; NT-proBNP, N-terminal
pro-B-type natriuretic peptide.
Clinical findings are presented as number of patients (%) with the respective
finding, while laboratory parameters are expressed as median (25th-75th
percentiles). Reference values (decision level for heart failure or myocardial
injury for NT-ProBNP and hs-cTnT respectively) are presented in parenthesis.
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Table 2 Significant results in relation to need of oxygen and impaired general condition at follow-up
Oxygen treatment Yes / No Impaired condition follow-up Yes / No
Laboratory results
Number of patients 9 / 18 13 / 13
Leukocyte count max (3.5-8.8 109/L) 13.0 (9.1-15.7) / 7.8 (6.3-9.2)** 6.5 (5.6-7.9) / 5.4 (5.0-8.5)
Creatinine max (<105 μmol/L) 276 (186–352) / 143 (111–237)* 69 (59–92) / 68 (53–92)
Albumin min (36–45 g/L) 21 (19–27) / 29 (25–31)** 44 (41–49) / 45 (42–46)
Cardiac biomarkers
NT-proBNP max (<150 ng/L) 8470 (2055–12511) / 860 (237–4024)** 75 (36–300) / 49 (15–108)
hs-cTnT max (<15 ng/L) 16 (8–22) / 6 (0–10)* 6 (0–8) / 0 (0–7)
Echocardiographic results
Number of patients 9 / 17 11 / 10
Heart rate (beats/min) 90 (81–104) / 66 (58–84)* 70 (58–84) / 71 (65–79)
Left ventricle IVRT (%) 11.9 (9.4-15.4) / 9.5 (7.8-10.9)* 9.7 (8.6-11.4) / 10.2 (8.7-12.1)
Systolic pulmonary artery pressure, mmHg 47 (35–47) / 33 (26–39)** 34 (29–39) / 27 (27–32)
Pulmonary vascular resistance (WU) 3.7 (2.8-4.4) / 2.3 (1.8-3.1)* 3.1 (1.9-3.7) / 1.8 (1.5-1.8)*
Pulmonary artery acceleration time (ms) 90 (70–111) / 127 (103–147)* 123 (104–137) / 124 (117–144)
TAPSE (mm) 20 (17–24) / 24 (21–30)* 21 (18–23) / 26 (21–29)
Lung function results
Number of patients 7 / 18 12 / 12
DLCO 53 (38–61) / 70 (62–82)* 74 (68–83) / 90 (84–101)*
DLCO, diffusing capacity of the lung for carbon monoxide; hs-cTnT, high-sensitivity cardiac troponin T; IVRT; isovolemic relaxation time (indexed to R-R interval);
max, maximum; min, minimum; NT-proBNP, N-terminal pro-B-type natriuretic peptide; TAPSE, tricuspid annular plane systolic excursion; WU, Wood units.
Results are expressed as median (25th-75th percentile). Laboratory reference values (decision level for heart failure or myocardial injury for NT-ProBNP and hs-cTnT
respectively) are presented in parenthesis. P-values, determined by Mann–Whitney U test, are expressed as * < 0.05, ** < 0.01.
Table 3 Lung function and chest high-resolution computed tomography results in acute phase and at follow-up
Acute phase Follow-up P-valuea
Lung function results
Number of patients 25 24 -
Days post onset of disease 7 (5–9) 98 (88–115) -
VC 103 (93–113) 112 (103–120) <0.001
TLC 105 (92–115) 109 (95–112) <0.05
FEV1 94 (77–104) 102 (93–117) <0.001
FEV1/VC 94 (88–99) 95 (86–101) ns
DLCO 67 (54–76) 83 (70–94) <0.001
Chest HRCT results
Number of patients 24 14b -
Days post onset of disease 6 (5–7) 100 (94–110) -
Pleural effusion 9 (38%) 0 -
Pulmonary oedema 5 (21%) 1 (4%) -
Enlarged thoracic lymph nodes 4 (17%) 0 -
Pericardial effusion 2 (8%) 0 -
Pneumonic infiltrate 1 (4%) 0 -
aDetermined by Wilcoxon signed-ranks test, bRadiological follow-up (X-ray or HRCT, when indicated) were performed in 14 patients with pathological findings.
DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 second; HRCT, high-resolution computed tomography; TLC, total
lung capacity; VC, vital capacity.
Results are expressed as median (25th-75th percentile) as percentage of predicted value for lung function and number of patients (%) with the respective finding
for chest HRCT.
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LA and LV (Table 4). Compared to patients without
need for oxygen supplementation, those requiring oxy-
gen treatment had RV systolic involvement indicated by
significantly higher PVR and sPAP, shorter pulmonary
artery acceleration time and lower TAPSE, along with
faster heart rate and longer LV IVRT (Table 2). There
was also a tendency to a longer RV IVRT in patients requi-
ring oxygen (P = 0.070). Patients with pulmonary oedema
had lower cardiac output, compared to those without pul-
monary oedema [3.7 (3.0-4.4) and 5.3 (4.4-6.1) respectively;
P < 0.05]. There were no significant differences in any echo-
cardiographic parameter, when comparing female and male
patients (data not shown).
At follow-up, there were significant improvements in
stroke volume and atrial myocardial contraction during
late diastole (Table 4). Otherwise, all the abnormal find-
ings for LV and RV function as well as pulmonary haemo-
dynamic in the acute phase were returning to normal but
had not changed significantly. Furthermore, patients ex-
periencing impaired general condition at follow-up had
significantly higher PVR, together with non-significantly
higher sPAP (P = 0.091) and lower TAPSE (P = 0.052),
when compared to those feeling fully recovered (Table 2).
Electrocardiography
ECG was recorded in 27 patients in the acute phase 5
(5–7) days and in 22 patients at follow-up 114 (99–155)
days post onset of disease. In the acute phase, patho-
logical ECG was evident in seven patients (26%). T-wave
changes were seen in all abnormal ECGs and atrial fibril-
lation was noted in two patients. There was no recorded
ST-segment alteration or conduction disturbance. At
follow-up, one patient still had atrial fibrillation, while
the other had regained sinus rhythm, yet with remaining
T-wave changes. The other patients’ ECGs were normal
at follow-up.
Cardiac biomarkers
NT-proBNP sampled on day of inclusion was patho-
logically elevated (>150 ng L-1) in 21 patients (78%), in-
creased during hospitalisation and peaked in median
8 days post onset of disease (Table 1). The maximum
level of NT-ProBNP was positively correlated to both
PVR (r 0.538, P < 0.05) and sPAP (r 0.412, P = 0.071) but
inversely correlated to DLCO (r −0.436, P < 0.05). Higher
NT-proBNP concentrations were found in patients with
pulmonary oedema (P < 0.01, data not shown). Eight
patients (30%) displayed hs-cTnT concentrations above
myocardial injury decision level (≥15 ng L-1). Patients
with pathologically elevated hs-cTnT had higher NT-
ProBNP levels, when compared to patients with normal
hs-cTnT (P < 0.01, data not shown). Patients requiring
oxygen treatment had significantly higher concentra-
tions of NT-proBNP and hs-cTnT, compared to those
not needing oxygen (Table 2). There were no significant
differences in NT-ProBNP or hs-cTnT concentrations,
when comparing male and female patients (data not shown).
At follow-up, NT-ProBNP and hs-cTnT concentrations
had significantly returned to normal (Table 1), however
there was an inverse correlation between patients’ NT-
proBNP level and DLCO (r −0.576, P < 0.01).
DIC-scoring
Overt DIC was established in 8 patients (30%). There
were no significant differences in need of oxygen, DLCO
or any parameter of cardiac function measured by echo-
cardiography, when comparing patients with or without
DIC (data not shown).
Discussion
In the present study, we aimed to study cardiopulmo-
nary involvement in patients with PUUV-infection. The
results revealed that a majority of the patients experienced
dry cough and/or dyspnea and almost all displayed im-
paired DLCO, indicating involvement of the lower airways
and lung parenchyma. Even though DLCO improved after
3 months, it remained subnormal in more than one-third
of the patients. Interestingly, patients reporting impaired
general condition after 3 months had significantly lower
DLCO compared to those who had recovered fully. This
finding further implies pulmonary involvement in the
pathogenesis of PUUV-infection and also indicates a
Figure 1 Chest high-resolution computed tomography image
from a patient with Puumala hantavirus infection. Investigation
was performed four days post onset of disease and shows bilateral
pleural effusion and pulmonary oedema in a previously healthy
non-smoking patient with pronounced clinical lung manifestations.
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possible explanation to the clinical observation of long-
lasting fatigue commonly reported by the patients.
Thoracic effusions or pulmonary oedema, also found
in patients with HPS [4-6], was demonstrated by HRCT
in almost half of the patients. Echocardiography investiga-
tion did not reveal volume/pressure overload or evidence
of elevated pulmonary capillary wedge pressure (normal
LA/LV size and normal pulmonary venous and trans-
mitral flow pattern). Therefore, we concluded that, similar
to HPS, the pulmonary oedema was non-cardiogenic and
instead related to increased capillary permeability that
together with parenchymal inflammation most likely is
responsible for the impaired gas diffusing capacity seen
in the patients. The present HRCT results are supported
by previous smaller CT or HRCT studies of patients
with PUUV-infection [13,14].
As hypothesised, echocardiography results demonstrated
abnormalities, mainly on the right-heart with increased
Table 4 Echocardiographic results in patients with Puumala hantavirus infection, compared to healthy controls
Healthy controls Acute phase Follow-up
Number of patients 25 26a 21
Days post onset of disease - 7 (6–9) 94 (89–114)
Age (years) 56 (48–65) 57 (47–65) 54 (45–64)
Females/Males 17 / 8 18 / 8 13 / 8
Heart rate (beats/min) 59 (52–67) 80 (60–91)** 70 (61–83)
Left heart function
Left atrium diameter (mm) 35 (32–39) 35 (30–40) 36 (31–39)
Interventricular septum diastole (mm) 9 (8–11) 9 (8–11) 9 (8–10)
Left ventricular diameter diastole (mm) 49 (46–53) 49 (44–51) 47 (45–50)
Left ventricular diameter systole (mm) 30 (25–31) 31 (28–35)* 29 (28–31)
Posterior wall diastole (mm) 8 (7–9) 7 (7–8)* 7 (7–8)
Left ventricle ejection fraction (%) 0.70 (0.62-0.74) 0.60 (0.55-0.70)** 0.63 (0.59-0.66)
Left ventricle stroke volume (mL) 74 (61–86) 62 (53–80) 76 (69–85)‡
Cardiac output (L/min) 4.2 (3.6-5.0) 4.8 (4.0-5.7) 5.5 (4.4-6.4)
Mitral flow deceleration time (ms) 185 (148–225) 160 (136–188) 161 (124–209)
Mitral flow E/A 1.0 (0.8-1.3) 1.2 (1.0-1.6) 1.1 (0.8-1.4)
Pulmonary venous flow S/D 1.3 (1.0-1.5) 1.2 (1.0-1.9) 1.4 (1.2-2.0)
Left ventricle IVRT (%) 8.3 (6.6-9.8) 9.9 (8.9-11.9)* 10.0 (8.7-11.8)
Right heart function
Systolic pulmonary artery pressure (mmHg) 26 (23–31) 36 (31–46)** 29 (27–36)
Pulmonary vascular resistance (WU) 1.7 (1.4-2.7) 2.9 (2.1-3.5)* 1.8 (1.6-3.1)
Pulmonary artery acceleration time (ms) 137 (129–145) 116 (90–142)* 124 (110–133)
Right ventricle IVRT (%) 4.8 (2.5-7.6) 7.3 (4.0-9.0) 5.0 (3.3-8.8)
TAPSE (mm) 23 (21–27) 24 (20–27) 22 (20–29)
Left ventricular strain rate
Ventricular systole (1/s) 0.87 (0.76-0.96) 0.94 (0.77-1.10) 0.92 (0.75-1.13)
Early diastole (1/s) 0.98 (0.87-1.16) 1.00 (0.60-1.51) 0.89 (0.69-1.25)
Late atrial diastole (1/s) 0.90 (0.84-1.05) 0.70 (0.52-0.86)** 0.91 (0.60-1.12)‡‡
Left atrial strain rate
Ventricular systole (1/s) 1.41 (1.06-1.69) 1.28 (0.93-1.69) 1.69 (1.37-1.99)
Early diastole (1/s) 1.40 (1.16-1.86) 1.24 (0.76-1.94) 1.71 (0.94-2.14)
Late atrial diastole (1/s) 1.70 (1.25-1.97) 1.34 (0.91-1.57)** 1.72 (1.26-2.13)‡
aOne patient with heart failure was omitted from statistical comparison with controls. E/A, ratio of trans-mitral early to late diastolic flow velocities; IVRT,
isovolemic relaxation time (expressed as ratio of R-R interval); S/D, ratio of pulmonary venous systolic to diastolic flow velocities; TAPSE, tricuspid annular plane
systolic excursion; WU, Wood units.
Data are presented as median (25th-75th percentiles). P-values, determined by Mann–Whitney U test or Wilcoxon signed-ranks test, are expressed as * < 0.05,
** < 0.01 comparing patients and controls; ‡ < 0.05, ‡‡ < 0.01 comparing patients in acute phase and at follow-up.
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pulmonary vascular resistance, leading to elevated pul-
monary artery systolic pressure, also described in HPS
and in patients with acute respiratory distress syndrome
[5,36]. The pathogenesis of increased PVR is likely multi-
factorial. Plausible mechanisms could include inflamma-
tion of pulmonary microvasculature, increased interstitial
pressure, stress-induced arterial constriction and diffuse
microembolism or thrombosis in the pulmonary vascula-
ture. Hantavirus mainly infects vascular endothelial cells
[37]. Both PUUV and HPS-related Sin Nombre virus have
been demonstrated to replicate in pulmonary capillary
endothelial cells, inducing inflammatory changes in the
endothelium and capillary leakage that has been attrib-
uted to effects of vascular endothelial growth factor
[11,16,17,37-40]. In addition, vascular endothelial growth
factor has also been suggested to play a central role in
development of pulmonary hypertension [41]. One may
speculate that hantavirus infection in the pulmonary
vascular endothelium leads to elevation of PVR and sec-
ondary pulmonary hypertension by means of endothelial
inflammation and increased pulmonary interstitial pres-
sure due to related vascular leakage. Pulmonary micro-
embolism in PUUV-infection could be supported by the
finding of pulmonary embolism in one patient in the
current cohort and previously reported observations of
symptomatic thromboembolism in survivors and evident
scattered pulmonary microthrombosis in lethal cases
[11,35]. In addition, DIC has been established in up to
one out of four PUUV-infected patients [35,42]. How-
ever, in the present study, we could not establish any
relation between the presence of DIC and increased
PVR, making this mechanism less likely.
Similar to patients with bacterial sepsis [43], the PUUV-
infected patients were hypotensive. This is likely a result
of peripheral vasodilatation or myocardial depression due
to pro-inflammatory cytokines [44,45], previously shown
to be associated with hypotension in HFRS patients [46].
In contrast to the normal circulatory state of sepsis,
PUUV-infected patients did not display an elevated car-
diac output during the acute phase, when compared to
controls or follow-up. This observation could specula-
tively be caused by myocardial depression in the patients,
as described in HPS and in septic cardiomyopathy [43,47].
In the present study, patients displayed impaired atrial
myocardial contraction. It is difficult to provide a clear
explanation for this finding but it may be related to an
increased LA wall stress and/or small increases in pul-
monary capillary wedge pressure or to the higher heart
rate in these patients. The lower LV ejection fraction
and prolonged LV IVRT in PUUV-infected patients,
compared to controls, were rarely subnormal and indi-
cate trivial systolic and diastolic left ventricle dysfunc-
tion. Similar findings for LV ejection fraction have been
reported in patients with PUUV-infection and patients
surviving Sin Nombre virus-related HPS, whereas HPS
fatal cases displayed pathologically reduced LV ejection
fraction [5,19].
At follow up, compared to the acute phase, we found
a significant increase in LV stroke volume and atrial
myocardial contraction, while other determined echo-
cardiography variables were non-significantly normalis-
ing, indicating slow functional haemodynamical recovery
despite significant recovery in gas diffusing capacity. Not-
ably, patients experiencing impaired general condition at
follow-up had significantly higher PVR, which may sug-
gest remaining PUUV-related pulmonary vascular effects
in patients with prolonged clinical recovery.
The cardiac biomarker NT-ProBNP is used to detect
heart failure but has not previously been evaluated in
hantavirus infections. NT-ProBNP is secreted to the cir-
culation as a consequence of myocardial stretch and
dysfunction. It has vasodilatory and pro-diuretic effects
that lead to reduced pre-load and lowered cardiac out-
put [48,49]. The marked elevation of NT-ProBNP in the
PUUV-infected patients is not easily explained, as overt
left or right heart failure could not be established by
echocardiography. However, it has been documented
that NT-ProBNP can be increased in sepsis due to pro-
inflammatory cytokines even without echocardiographic
evidence of ventricular heart failure [50-53], as well as
in patients suffering from tuberculosis and hepatitis C-
infection [54,55]. Another contributing factor to increased
NT-ProBNP in the PUUV-infected patients may be im-
paired renal elimination, since NT-ProBNP levels peaked
during the late acute phase when patients were experien-
cing renal failure. However, the importance of renal clear-
ance of NT-ProBNP is controversial and has been shown
to account for only 15-20% of the total elimination
[56,57]. Additionally, in almost all patients, an increase
in NT-ProBNP was noted already on day of inclusion
and prior to onset of renal failure. In the present study,
we demonstrate that NT-ProBNP was inversely associ-
ated with patient’s gas diffusing capacity but positively
correlated to PVR, in similarity with patients with pul-
monary hypertension [58]. Furthermore, PUUV-infected
patients with pulmonary oedema had higher levels of
NT-ProBNP, possibly reflecting NT-ProBNP elevation
in response to increased right ventricular load.
High-sensitivity troponin T, a biomarker of myocardial
injury, was slightly elevated in one-third of the patients
in the present study, indicating microscopic myocardial
cell damage. Slightly less frequent than previously reported,
pathological electrocardiograms were found in one-fourth
of the PUUV-infected patients during the acute phase
of disease [18,19]. No patient could be diagnosed with
myocarditis, based on evaluation of clinical features,
troponin T and ECG findings, which is in concordance
with a previous study [19].
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The major strengths of the present study are the simul-
taneous use of different diagnostic methods to evaluate
cardiopulmonary manifestations and underlying patho-
physiological mechanisms in a relatively large patient
population during the acute and follow-up phases of
PUUV-infection. However, there are some limitations.
Many echocardiography variables are estimates. Although
invasive monitoring using a pulmonary artery catheter
would have given more accurate readings, in our opinion,
this was not possible, given the presence of coagulopa-
thy. Consequently, non-invasive measurements were
chosen. Also, not all patients underwent follow-up
echocardiography.
Conclusions
Cardiopulmonary manifestations in PUUV-infection could
be established in a majority of investigated patients, cha-
racterised by signs of pulmonary capillary leakage most
likely responsible for the impairment of gas diffusing
capacity and increased pulmonary vascular resistance
with secondary pulmonary hypertension. In addition,
levels of NT-proBNP were markedly elevated, indicating
myocardial distress. Cardiopulmonary effects of PUUV-
infection were long-lasting and had implications on
patients’ recovery.
More studies are needed to further establish the mecha-
nisms of increased pulmonary vascular resistance in PUUV-
related hantavirus disease, and to evaluate the long-term
effects of PUUV-infection on cardiopulmonary function.
Abbreviations
DIC: Disseminated intravascular coagulation; DLCO: Diffusing capacity of the lung
for carbon monoxide; HPS: Hantavirus pulmonary syndrome; HFRS: Haemorrhagic
fever with renal syndrome; HRCT: High-resolution computed tomography;
hs-cTnT: High-sensitivity cardiac troponin T; IVRT: Isovolemic relaxation time;
LA: Left atrium; LV: Left ventricle; NT-ProBNP: N-terminal pro-B-type
natriuretic peptide; PUUV: Puumala hantavirus; PVR: Pulmonary vascular
resistance; RV: Right ventricle; sPAP: Systolic pulmonary artery pressure;
TAPSE: Tricuspid annular plane systolic excursion.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JR conceived and designed the study, enrolled study subjects, collected data,
performed statistical analyses and was principally responsible for manuscript
preparation. PL contributed to study design, performed and analysed
echocardiographic examinations and edited the manuscript. KS performed
HRCT studies and interpretations and drafted the manuscript. MH
contributed to study design, analysed ECG, gave assistance in interpretation
of echocardiographic and cardiac biomarker results and drafted the
manuscript. AB contributed to study design, assisted with interpretation of
lung function and HRCT results and edited the manuscript. CA supervised
study design, enrolled study subjects and edited the manuscript. All authors
read and approved the final manuscript.
Authors’ information
JR: MD, PhD student and consultant in infectious diseases with clinical
interest in hantavirus infection and patient care. PL: PhD and associate
professor with long experience in echocardiography and heart physiology.
KS: MD and senior consultant in diagnostic radiology with special interest in
pulmonary imaging. MH: MD, PhD student and senior consultant in
cardiology. AB: MD, PhD, professor and senior consultant in respiratory
medicine with long experience in pulmonary research and clinical care.
CA: MD, PhD, professor and senior consultant in infectious diseases with
a special interest in hantavirus research and clinical care.
Acknowledgments
We thank the patients for their participation in the study; the personnel at
the Departments of Infectious Diseases, Respiratory Medicine & Allergy,
Diagnostic Radiology, and Heart Centre, Umeå University Hospital, for
assistance in the study.
This project was supported by grants from the Swedish Heart-Lung
Foundation, the Heart Foundation of Northern Sweden, the County Councils
of Northern Sweden, the County Council of Västerbotten and the Medical
Faculty of Umeå University.
Author details
1Department of Clinical Microbiology, Umeå University, SE - 901 85 Umeå,
Sweden. 2Department of Surgical and Perioperative Sciences, Umeå
University, Umeå, Sweden. 3Department of Radiation Sciences, Umeå
University, Umeå, Sweden. 4Department of Public Health and Clinical
Medicine, Clinical Physiology, Heart Centre, Umeå University, Umeå, Sweden.
5Department of Public Health and Clinical Medicine, Umeå University, Umeå,
Sweden.
Received: 20 June 2013 Accepted: 17 October 2013
Published: 28 October 2013
References
1. Jonsson CB, Figueiredo LT, Vapalahti O: A global perspective on hantavirus
ecology, epidemiology, and disease. Clin Microbiol Rev 2010, 23:412–441.
2. Botten J, Mirowsky K, Ye C, Gottlieb K, Saavedra M, Ponce L, Hjelle B:
Shedding and intracage transmission of Sin Nombre hantavirus in the
deer mouse (Peromyscus maniculatus) model. J Virol 2002, 76:7587–7594.
3. Hardestam J, Karlsson M, Falk KI, Olsson G, Klingström J, Lundkvist Å:
Puumala hantavirus excretion kinetics in bank voles (Myodes glareolus).
Emerg Infect Dis 2008, 14:1209–1215.
4. Duchin JS, Koster FT, Peters CJ, Simpson GL, Tempest B, Zaki SR, Ksiazek TG,
Rollin PE, Nichol S, Umland ET, et al: Hantavirus pulmonary syndrome:
a clinical description of 17 patients with a newly recognized disease.
The Hantavirus Study Group. N Engl J Med 1994, 330:949–955.
5. Hallin GW, Simpson SQ, Crowell RE, James DS, Koster FT, Mertz GJ, Levy H:
Cardiopulmonary manifestations of hantavirus pulmonary syndrome.
Crit Care Med 1996, 24:252–258.
6. Castillo C, Naranjo J, Sepulveda A, Ossa G, Levy H: Hantavirus pulmonary
syndrome due to Andes virus in Temuco, Chile: clinical experience with
16 adults. Chest 2001, 120:548–554.
7. Vapalahti O, Mustonen J, Lundkvist Å, Henttonen H, Plyusnin A, Vaheri A:
Hantavirus infections in Europe. Lancet Infect Dis 2003, 3:653–661.
8. Clement J, Colson P, McKenna P: Hantavirus pulmonary syndrome in
New England and Europe. N Engl J Med 1994, 331:545–546.
9. Linderholm M, Sandström T, Rinnström O, Groth S, Blomberg A, Tärnvik A:
Impaired pulmonary function in patients with hemorrhagic fever with
renal syndrome. Clin Infect Dis 1997, 25:1084–1089.
10. Seitsonen E, Hynninen M, Kolho E, Kallio-Kokko H, Pettilä V: Corticosteroids
combined with continuous veno-venous hemodiafiltration for treatment
of hantavirus pulmonary syndrome caused by Puumala virus infection.
Eur J Clin Microbiol Infect Dis 2006, 25:261–266.
11. Rasmuson J, Andersson C, Norrman E, Haney M, Evander M, Ahlm C: Time
to revise the paradigm of hantavirus syndromes? Hantavirus pulmonary
syndrome caused by European hantavirus. Eur J Clin Microbiol Infect Dis
2011, 30:685–690.
12. Rasmuson J, Pourazar J, Linderholm M, Sandström T, Blomberg A, Ahlm C:
Presence of activated airway T lymphocytes in human puumala
hantavirus disease. Chest 2011, 140:715–722.
13. Linderholm M, Billström A, Settergren B, Tärnvik A: Pulmonary involvement
in nephropathia epidemica as demonstrated by computed tomography.
Infection 1992, 20:263–266.
14. Paakkala A, Järvenpää R, Mäkelä S, Huhtala H, Mustonen J: Pulmonary high-
resolution computed tomography findings in nephropathia epidemica.
Eur J Radiol 2012, 81:1707–1711.
Rasmuson et al. BMC Infectious Diseases 2013, 13:501 Page 9 of 11
http://www.biomedcentral.com/1471-2334/13/501
15. Linderholm M, Bjermer L, Juto P, Roos G, Sandström T, Settergren B, Tärnvik A:
Local host response in the lower respiratory tract in nephropathia
epidemica. Scand J Infect Dis 1993, 25:639–646.
16. Nolte KB, Feddersen RM, Foucar K, Zaki SR, Koster FT, Madar D, Merlin TL,
McFeeley PJ, Umland ET, Zumwalt RE: Hantavirus pulmonary syndrome in
the United States: a pathological description of a disease caused by a
new agent. Hum Pathol 1995, 26:110–120.
17. Zaki SR, Greer PW, Coffield LM, Goldsmith CS, Nolte KB, Foucar K, Feddersen
RM, Zumwalt RE, Miller GL, Khan AS, et al: Hantavirus pulmonary syndrome.
Pathogenesis of an emerging infectious disease. Am J Pathol 1995,
146:552–579.
18. Puljiz I, Kuzman I, Markotic A, Turcinov D, Matic M, Makek N:
Electrocardiographic changes in patients with haemorrhagic fever with
renal syndrome. Scand J Infect Dis 2005, 37:594–598.
19. Mäkelä S, Kokkonen L, Ala-Houhala I, Groundstroem K, Harmoinen A,
Huhtala H, Hurme M, Paakkala A, Pörsti I, Virtanen V, et al: More than half of
the patients with acute Puumala hantavirus infection have abnormal
cardiac findings. Scand J Infect Dis 2009, 41:57–62.
20. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R,
Enright P, van der Grinten CP, Gustafsson P, et al: Standardisation of
spirometry. Eur Respir J 2005, 26:319–338.
21. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V,
Burgos F, Casaburi R, Coates A, Enright P, et al: Standardisation of the
single-breath determination of carbon monoxide uptake in the lung.
Eur Respir J 2005, 26:720–735.
22. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC:
Lung volumes and forced ventilatory flows. Report Working Party
Standardization of Lung Function Tests, European Community for Steel
and Coal. Official Statement of the European Respiratory Society.
Eur Respir J Suppl 1993, 16:5–40.
23. Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC: Standardization of the
measurement of transfer factor (diffusing capacity). Report Working
Party Standardization of Lung Function Tests, European Community for
Steel and Coal. Official Statement of the European Respiratory Society.
Eur Respir J Suppl 1993, 16:41–52.
24. Quinones MA, Otto CM, Stoddard M, Waggoner A, Zoghbi WA:
Recommendations for quantification of Doppler echocardiography:
a report from the Doppler Quantification Task Force of the
Nomenclature and Standards Committee of the American Society of
Echocardiography. J Am Soc Echocardiogr 2002, 15:167–184.
25. Sahn DJ, DeMaria A, Kisslo J, Weyman A: Recommendations regarding
quantitation in M-mode echocardiography: results of a survey of
echocardiographic measurements. Circulation 1978, 58:1072–1083.
26. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA,
Picard MH, Roman MJ, Seward J, Shanewise JS, et al: Recommendations for
chamber quantification: a report from the American Society of
Echocardiography’s Guidelines and Standards Committee and the
Chamber Quantification Writing Group, developed in conjunction with
the European Association of Echocardiography, a branch of the European
Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440–1463.
27. Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA,
Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A:
Recommendations for the evaluation of left ventricular diastolic function
by echocardiography. Eur J Echocardiogr 2009, 10:165–193.
28. Chemla D, Castelain V, Humbert M, Hebert JL, Simonneau G, Lecarpentier Y,
Herve P: New formula for predicting mean pulmonary artery pressure
using systolic pulmonary artery pressure. Chest 2004, 126:1313–1317.
29. Lindqvist P, Söderberg S, Gonzalez MC, Tossavainen E, Henein MY:
Echocardiography based estimation of pulmonary vascular resistance in
patients with pulmonary hypertension: a simultaneous Doppler
echocardiography and cardiac catheterization study. Eur J Echocardiogr
2011, 12:961–966.
30. Wahl A, Praz F, Schwerzmann M, Bonel H, Koestner SC, Hullin R, Schmid JP,
Stuber T, Delacretaz E, Hess OM, et al: Assessment of right ventricular
systolic function: comparison between cardiac magnetic resonance
derived ejection fraction and pulsed-wave tissue Doppler imaging of the
tricuspid annulus. Int J Cardiol 2011, 151:58–62.
31. Tossavainen E, Söderberg S, Grönlund C, Gonzalez M, Henein MY, Lindqvist P:
Pulmonary artery acceleration time in identifying pulmonary hypertension
patients with raised pulmonary vascular resistance. Eur Heart J Cardiovasc
Imaging. in press.
32. Lindqvist P, Waldenström A, Wikström G, Kazzam E: Right ventricular
myocardial isovolumic relaxation time and pulmonary pressure.
Clin Physiol Funct Imaging 2006, 26:1–8.
33. Henein M, Zhao Y, Henein MY, Lindqvist P: Disturbed left atrial mechanical
function in paroxysmal atrial fibrillation: a speckle tracking study. Int J
Cardiol 2012, 155:437–441.
34. Lindqvist P, Zhao Y, Bajraktari G, Holmgren A, Henein MY: Aortic valve
replacement normalizes left ventricular twist function. Interact Cardiovasc
Thorac Surg 2011, 12:701–706.
35. Sundberg E, Hultdin J, Nilsson S, Ahlm C: Evidence of disseminated
intravascular coagulation in a hemorrhagic fever with renal syndrome-
scoring models and severe illness. PLoS One 2011, 6:e21134.
36. Zapol WM, Snider MT: Pulmonary hypertension in severe acute
respiratory failure. N Engl J Med 1977, 296:476–480.
37. Mackow ER, Gavrilovskaya IN: Hantavirus regulation of endothelial cell
functions. Thromb Haemost 2009, 102:1030–1041.
38. Geimonen E, Neff S, Raymond T, Kocer SS, Gavrilovskaya IN, Mackow ER:
Pathogenic and nonpathogenic hantaviruses differentially regulate
endothelial cell responses. Proc Natl Acad Sci U S A 2002, 99:13837–13842.
39. Hayasaka D, Maeda K, Ennis FA, Terajima M: Increased permeability of
human endothelial cell line EA.hy926 induced by hantavirus-specific
cytotoxic T lymphocytes. Virus Res 2007, 123:120–127.
40. Shrivastava-Ranjan P, Rollin PE, Spiropoulou CF: Andes virus disrupts the
endothelial cell barrier by induction of vascular endothelial growth
factor and downregulation of VE-cadherin. J Virol 2010, 84:11227–11234.
41. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F,
Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al: Inflammation,
growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol
2009, 54(1 Suppl):S10–19.
42. Laine O, Mäkelä S, Mustonen J, Huhtala H, Szanto T, Vaheri A, Lassila R,
Joutsi-Korhonen L: Enhanced thrombin formation and fibrinolysis during
acute Puumala hantavirus infection. Thromb Res 2010, 126:154–158.
43. Young JD: The heart and circulation in severe sepsis. Br J Anaesth 2004,
93:114–120.
44. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL:
Negative inotropic effects of cytokines on the heart mediated by nitric
oxide. Science 1992, 257:387–389.
45. Hartemink KJ, Groeneveld AB: The hemodynamics of human septic shock
relate to circulating innate immunity factors. Immunol Invest 2010,
39:849–862.
46. Linderholm M, Groeneveld PH, Tärnvik A: Increased production of nitric
oxide in patients with hemorrhagic fever with renal syndrome - relation to
arterial hypotension and tumor necrosis factor. Infection 1996, 24:337–340.
47. Saggioro FP, Rossi MA, Duarte MI, Martin CC, Alves VA, Moreli ML,
Figueiredo LT, Moreira JE, Borges AA, Neder L: Hantavirus infection
induces a typical myocarditis that may be responsible for myocardial
depression and shock in hantavirus pulmonary syndrome. J Infect Dis
2007, 195:1541–1549.
48. Woods RL: Cardioprotective functions of atrial natriuretic peptide and
B-type natriuretic peptide: a brief review. Clin Exp Pharmacol Physiol
2004, 31:791–794.
49. Kim HN, Januzzi JL Jr: Natriuretic peptide testing in heart failure.
Circulation 2011, 123:2015–2019.
50. Witthaut R, Busch C, Fraunberger P, Walli A, Seidel D, Pilz G, Stuttmann R,
Speichermann N, Verner L, Werdan K: Plasma atrial natriuretic peptide and
brain natriuretic peptide are increased in septic shock: impact of
interleukin-6 and sepsis-associated left ventricular dysfunction.
Intensive Care Med 2003, 29:1696–1702.
51. Bar SL, Swiggum E, Straatman L, Ignaszewski A: Nonheart failure-associated
elevation of amino terminal pro-brain natriuretic peptide in the setting
of sepsis. Can J Cardiol 2006, 22:263–266.
52. Shor R, Rozenman Y, Bolshinsky A, Harpaz D, Tilis Y, Matas Z, Fux A, Boaz M,
Halabe A: BNP in septic patients without systolic myocardial dysfunction.
Eur J Intern Med 2006, 17:536–540.
53. Hartemink KJ, Twisk JW, Groeneveld AB: High circulating N-terminal
pro-B-type natriuretic peptide is associated with greater systolic
cardiac dysfunction and nonresponsiveness to fluids in septic vs
nonseptic critically ill patients. J Crit Care 2011, 26. 108 e1-8.
54. Bar SL, Sayeh N, Ignaszewski AP: Elevated N-terminal pro-brain natriuretic
peptide in Mycobacterium tuberculosis pulmonary infection without
myocardial dysfunction. Can J Cardiol 2009, 25:223–225.
Rasmuson et al. BMC Infectious Diseases 2013, 13:501 Page 10 of 11
http://www.biomedcentral.com/1471-2334/13/501
55. Antonelli A, Ferri C, Ferrari SM, Marchi S, De Bortoli N, Sansonno D,
Chiavacci C, Ferrannini E, Fallahi P: N-terminal pro-brain natriuretic
peptide and tumor necrosis factor-alpha both are increased in patients
with Hepatitis C. J Interferon Cytokine Res 2010, 30:359–363.
56. Schou M, Dalsgaard MK, Clemmesen O, Dawson EA, Yoshiga CC, Nielsen HB,
Gustafsson F, Hildebrandt PR, Secher NH: Kidneys extract BNP and NT-proBNP
in healthy young men. J Appl Physiol 2005, 99:1676–1680.
57. van Kimmenade RR, Januzzi JL Jr, Bakker JA, Houben AJ, Rennenberg R,
Kroon AA, Crijns HJ, van Dieijen-Visser MP, de Leeuw PW, Pinto YM: Renal
clearance of B-type natriuretic peptide and amino terminal pro-B-type
natriuretic peptide a mechanistic study in hypertensive subjects. J Am
Coll Cardiol 2009, 53:884–890.
58. Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P,
Szturmowicz M: Serum N-terminal brain natriuretic peptide as a prognostic
parameter in patients with pulmonary hypertension. Chest 2006,
129:1313–1321.
doi:10.1186/1471-2334-13-501
Cite this article as: Rasmuson et al.: Cardiopulmonary involvement in
Puumala hantavirus infection. BMC Infectious Diseases 2013 13:501.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rasmuson et al. BMC Infectious Diseases 2013, 13:501 Page 11 of 11
http://www.biomedcentral.com/1471-2334/13/501
